Laronde
Sail Biomedicines is a biotechnology company pioneering programmable RNA medicines using its proprietary platform that integrates evolution and AI. The company has developed Endless RNA (eRNA), a novel circular RNA technology that enables durable and programmable protein expression inside the body. Sail also innovates in nanoparticle design with expanded natural chemistries to enhance RNA delivery, enabling unique tissue targeting and repeated dosing. Leveraging proprietary AI algorithms and rapid prototyping, Sail aims to develop RNA medicines for autoimmune, metabolic, infectious, and rare diseases, positioning itself at the forefront of RNA therapeutic innovation with a comprehensive bioplatform and product pipeline.
Laronde
Sail Biomedicines is a biotechnology company pioneering programmable RNA medicines using its proprietary platform that integrates evolution and AI. The company has developed Endless RNA (eRNA), a novel circular RNA technology that enables durable and programmable protein expression inside the body. Sail also innovates in nanoparticle design with expanded natural chemistries to enhance RNA delivery, enabling unique tissue targeting and repeated dosing. Leveraging proprietary AI algorithms and rapid prototyping, Sail aims to develop RNA medicines for autoimmune, metabolic, infectious, and rare diseases, positioning itself at the forefront of RNA therapeutic innovation with a comprehensive bioplatform and product pipeline.
TL;DR
Headquarters: Cambridge, Massachusetts
Founded: 2017
Platform: Endless/circular RNA (eRNA) for durable, repeat-dosable in vivo protein expression
Acquisition: Merged/acquired into Sail Biomedicines (announced Oct 2023)
Notable financing: Series B announced Aug 30, 2021 led by Flagship Pioneering
Company Overview
Problem Domain
RNA therapeutics delivery and durable in vivo protein expression for autoimmune, metabolic, infectious, and rare diseases.
Founded
2017
Industry
Biotechnology
Funding Track Record
Series B reported in some sources as a large financing announced Aug 30, 2021; participant investors include institutional asset managers.
Investor Signal
“Flagship Pioneering led both Series A and Series B; Series B included institutional investors such as BlackRock, Invus, T. Rowe Price, Fidelity, and CPP Investments.”